Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $980.00

Posted by Brenda Bartman on Nov 2nd, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price objective upped by research analysts at Cantor Fitzgerald from $795.00 to $980.00 in a research report issued to clients and investors on Monday, Benzinga reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald‘s price target would suggest a potential upside of 5.62% from the stock’s previous close.

A number of other equities analysts have also weighed in on REGN. JPMorgan Chase & Co. lifted their price target on shares of Regeneron Pharmaceuticals from $900.00 to $950.00 and gave the company an “overweight” rating in a report on Tuesday, October 6th. HSBC lifted their target price on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the company a “buy” rating in a report on Thursday, September 10th. Evercore upped their price target on Regeneron Pharmaceuticals from $825.00 to $850.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. BMO Capital Markets raised their price objective on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock an “outperform” rating in a report on Wednesday, September 9th. Finally, Robert W. Baird lifted their price objective on Regeneron Pharmaceuticals from $742.00 to $761.00 and gave the company a “neutral” rating in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $872.00.

Get Our Latest Stock Analysis on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Price Performance

REGN opened at $927.89 on Monday. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.06 and a quick ratio of 3.66. The stock has a market capitalization of $95.54 billion, a price-to-earnings ratio of 20.49, a price-to-earnings-growth ratio of 1.57 and a beta of 0.10. The business has a 50-day moving average of $793.30 and a two-hundred day moving average of $738.05. Regeneron Pharmaceuticals has a 12 month low of $591.52 and a 12 month high of $935.35.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last announced its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, topping the consensus estimate of $16.51 by $3.56. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The business had revenue of $5.12 billion for the quarter, compared to analyst estimates of $4.58 billion. During the same period in the prior year, the firm posted $11.83 EPS. The company’s revenue was up 36.3% on a year-over-year basis. On average, research analysts expect that Regeneron Pharmaceuticals will post 49.10 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Andrew J. Murphy sold 4,147 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, October 14th. The shares were sold at an average price of $772.70, for a total transaction of $3,204,386.90. Following the sale, the insider owned 47,833 shares in the company, valued at $36,960,559.10. This trade represents a 7.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,131 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $857.39, for a total transaction of $969,708.09. Following the sale, the executive vice president directly owned 12,003 shares in the company, valued at $10,291,252.17. This trade represents a 8.61% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 8,093 shares of company stock worth $6,506,845 in the last ninety days. 6.97% of the stock is owned by corporate insiders.

Institutional Trading of Regeneron Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. purchased a new position in Regeneron Pharmaceuticals in the second quarter valued at about $5,682,636,000. State Street Corp increased its position in shares of Regeneron Pharmaceuticals by 3.6% in the 2nd quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock worth $3,014,621,000 after purchasing an additional 170,210 shares during the last quarter. Bank of America Corp DE lifted its position in shares of Regeneron Pharmaceuticals by 2.8% during the first quarter. Bank of America Corp DE now owns 1,189,584 shares of the biopharmaceutical company’s stock worth $919,120,000 after purchasing an additional 32,158 shares during the last quarter. Amundi increased its holdings in Regeneron Pharmaceuticals by 27.5% in the first quarter. Amundi now owns 1,009,798 shares of the biopharmaceutical company’s stock valued at $780,210,000 after buying an additional 217,892 shares during the last quarter. Finally, Legal & General Group Plc bought a new position in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $473,872,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

(Get Free Report)

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.